Epiduo is an anti-acne medication that is owned by Galderma Labs Lp. Its active ingredients are Adapalene and Benzoyl Peroxide and was first authorized for market use on 08 December, 2008.
The last patent for Epiduo is set to expire on 18 July, 2027. After this date, it is possible that generic versions of Epiduo will start to become available.
Epiduo is primarily used as a treatment for acne. Its two active ingredients, Adapalene and Benzoyl Peroxide, work together to kill acne-causing bacteria and reduce inflammation.
Epiduo has a total of 10 drug patents, out of which 4 have already expired. The remaining patents are set to expire between 2024 and 2027, which will likely pave the way for Epiduo generic versions to be released into the market. Below are the details of the patents: